25 XP   0   0   10

Biotest Aktiengesellschaft
Buy, Hold or Sell?

Let's analyse Biotest together

PenkeI guess you are interested in Biotest Aktiengesellschaft. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Biotest Aktiengesellschaft. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Biotest Aktiengesellschaft

I send you an email if I find something interesting about Biotest Aktiengesellschaft.

Quick analysis of Biotest (30 sec.)










What can you expect buying and holding a share of Biotest? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
90.0%

What is your share worth?

Current worth
€12.61
Expected worth in 1 year
€25.53
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
€12.92
Return On Investment
45.2%

For what price can you sell your share?

Current Price per Share
€28.60
Expected price per share
€22.80 - €30.40
How sure are you?
50%

1. Valuation of Biotest (5 min.)




Live pricePrice per Share (EOD)

€28.60

Intrinsic Value Per Share

€-8.99 - €9.37

Total Value Per Share

€3.61 - €21.98

2. Growth of Biotest (5 min.)




Is Biotest growing?

Current yearPrevious yearGrowGrow %
How rich?$537m$399.4m$137.5m25.6%

How much money is Biotest making?

Current yearPrevious yearGrowGrow %
Making money$136.7m-$34m$170.7m124.9%
Net Profit Margin18.6%-6.1%--

How much money comes from the company's main activities?

3. Financial Health of Biotest (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#103 / 1007

Most Revenue
#69 / 1007

Most Profit
#54 / 1007

Most Efficient
#93 / 1007

What can you expect buying and holding a share of Biotest? (5 min.)

Welcome investor! Biotest's management wants to use your money to grow the business. In return you get a share of Biotest.

What can you expect buying and holding a share of Biotest?

First you should know what it really means to hold a share of Biotest. And how you can make/lose money.

Speculation

The Price per Share of Biotest is €28.60. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Biotest.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biotest, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €12.61. Based on the TTM, the Book Value Change Per Share is €3.23 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Biotest.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps3.4512.1%3.4512.1%-0.86-3.0%-0.03-0.1%0.170.6%
Usd Book Value Change Per Share3.4812.2%3.4812.2%-0.25-0.9%0.020.1%0.030.1%
Usd Dividend Per Share0.000.0%0.000.0%0.020.1%0.020.1%0.060.2%
Usd Total Gains Per Share3.4812.2%3.4812.2%-0.23-0.8%0.040.1%0.100.3%
Usd Price Per Share33.37-33.37-36.60-32.77-54.55-
Price to Earnings Ratio9.66-9.66--42.58--50.21-8.79-
Price-to-Total Gains Ratio9.60-9.60--158.29--50.51-1,802.63-
Price to Book Ratio2.46-2.46-3.63-2.86-4.47-
Price-to-Total Gains Ratio9.60-9.60--158.29--50.51-1,802.63-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share30.7879
Number of shares32
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share3.480.02
Usd Total Gains Per Share3.480.04
Gains per Quarter (32 shares)111.251.20
Gains per Year (32 shares)445.014.81
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1044543523-5
20890880450
3013351325785
401780177091010
5022252215111315
6026702660131520
7031153105161825
8035603550182130
9040053995202335
10044504440222640

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%1.02.00.033.3%1.04.00.020.0%3.07.00.030.0%12.07.03.054.5%
Book Value Change Per Share1.00.00.0100.0%1.02.00.033.3%1.04.00.020.0%2.08.00.020.0%12.010.00.054.5%
Dividend per Share0.00.01.00.0%2.00.01.066.7%4.00.01.080.0%9.00.01.090.0%15.00.07.068.2%
Total Gains per Share1.00.00.0100.0%1.02.00.033.3%1.04.00.020.0%3.07.00.030.0%13.09.00.059.1%

Fundamentals of Biotest

About Biotest Aktiengesellschaft

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A.

Fundamental data was last updated by Penke on 2024-05-01 10:15:08.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Biotest Aktiengesellschaft.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Biotest earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • A Net Profit Margin of 18.6% means that €0.19 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Biotest Aktiengesellschaft:

  • The MRQ is 18.6%. The company is making a huge profit. +2
  • The TTM is 18.6%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ18.6%TTM18.6%0.0%
TTM18.6%YOY-6.1%+24.7%
TTM18.6%5Y-1.5%+20.0%
5Y-1.5%10Y1.8%-3.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.6%-207.2%+225.8%
TTM18.6%-214.6%+233.2%
YOY-6.1%-281.4%+275.3%
5Y-1.5%-428.1%+426.6%
10Y1.8%-595.4%+597.2%
1.1.2. Return on Assets

Shows how efficient Biotest is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • 8.8% Return on Assets means that Biotest generated €0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Biotest Aktiengesellschaft:

  • The MRQ is 8.8%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 8.8%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ8.8%TTM8.8%0.0%
TTM8.8%YOY-2.6%+11.4%
TTM8.8%5Y-0.6%+9.3%
5Y-0.6%10Y0.3%-0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.8%-12.9%+21.7%
TTM8.8%-12.3%+21.1%
YOY-2.6%-11.2%+8.6%
5Y-0.6%-13.5%+12.9%
10Y0.3%-15.1%+15.4%
1.1.3. Return on Equity

Shows how efficient Biotest is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • 25.5% Return on Equity means Biotest generated €0.25 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Biotest Aktiengesellschaft:

  • The MRQ is 25.5%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 25.5%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ25.5%TTM25.5%0.0%
TTM25.5%YOY-8.5%+34.0%
TTM25.5%5Y-1.6%+27.0%
5Y-1.6%10Y-0.1%-1.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ25.5%-16.5%+42.0%
TTM25.5%-15.7%+41.2%
YOY-8.5%-14.1%+5.6%
5Y-1.6%-18.8%+17.2%
10Y-0.1%-19.7%+19.6%

1.2. Operating Efficiency of Biotest Aktiengesellschaft.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Biotest is operating .

  • Measures how much profit Biotest makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • An Operating Margin of 19.0% means the company generated €0.19  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Biotest Aktiengesellschaft:

  • The MRQ is 19.0%. The company is operating efficient. +1
  • The TTM is 19.0%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ19.0%TTM19.0%0.0%
TTM19.0%YOY-2.5%+21.5%
TTM19.0%5Y0.4%+18.6%
5Y0.4%10Y4.7%-4.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.0%-287.3%+306.3%
TTM19.0%-226.2%+245.2%
YOY-2.5%-287.8%+285.3%
5Y0.4%-459.1%+459.5%
10Y4.7%-598.1%+602.8%
1.2.2. Operating Ratio

Measures how efficient Biotest is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.81 means that the operating costs are €0.81 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 0.810. The company is less efficient in keeping operating costs low.
  • The TTM is 0.810. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.810TTM0.8100.000
TTM0.810YOY1.016-0.207
TTM0.8105Y0.990-0.180
5Y0.99010Y0.994-0.005
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8103.246-2.436
TTM0.8103.303-2.493
YOY1.0163.753-2.737
5Y0.9905.557-4.567
10Y0.9947.396-6.402

1.3. Liquidity of Biotest Aktiengesellschaft.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Biotest is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.96 means the company has €1.96 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 1.963. The company is able to pay all its short-term debts. +1
  • The TTM is 1.963. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.963TTM1.9630.000
TTM1.963YOY4.757-2.794
TTM1.9635Y4.289-2.325
5Y4.28910Y4.031+0.258
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9633.821-1.858
TTM1.9634.161-2.198
YOY4.7575.313-0.556
5Y4.2896.113-1.824
10Y4.0316.474-2.443
1.3.2. Quick Ratio

Measures if Biotest is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • A Quick Ratio of 0.85 means the company can pay off €0.85 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 0.845. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.845. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.845TTM0.8450.000
TTM0.845YOY2.631-1.785
TTM0.8455Y2.235-1.389
5Y2.23510Y2.395-0.161
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8453.474-2.629
TTM0.8453.993-3.148
YOY2.6315.388-2.757
5Y2.2356.105-3.870
10Y2.3956.442-4.047

1.4. Solvency of Biotest Aktiengesellschaft.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Biotest assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Biotest to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.65 means that Biotest assets are financed with 65.5% credit (debt) and the remaining percentage (100% - 65.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 0.655. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.655. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.655TTM0.6550.000
TTM0.655YOY0.692-0.037
TTM0.6555Y0.636+0.018
5Y0.63610Y0.607+0.029
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6550.347+0.308
TTM0.6550.340+0.315
YOY0.6920.272+0.420
5Y0.6360.368+0.268
10Y0.6070.388+0.219
1.4.2. Debt to Equity Ratio

Measures if Biotest is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • A Debt to Equity ratio of 189.5% means that company has €1.89 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 1.895. The company is just able to pay all its debts with equity.
  • The TTM is 1.895. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.895TTM1.8950.000
TTM1.895YOY2.242-0.347
TTM1.8955Y1.785+0.110
5Y1.78510Y1.592+0.193
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8950.395+1.500
TTM1.8950.411+1.484
YOY2.2420.339+1.903
5Y1.7850.438+1.347
10Y1.5920.469+1.123

2. Market Valuation of Biotest Aktiengesellschaft

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Biotest generates.

  • Above 15 is considered overpriced but always compare Biotest to the Biotechnology industry mean.
  • A PE ratio of 9.66 means the investor is paying €9.66 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Biotest Aktiengesellschaft:

  • The EOD is 8.911. Based on the earnings, the company is underpriced. +1
  • The MRQ is 9.659. Based on the earnings, the company is underpriced. +1
  • The TTM is 9.659. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD8.911MRQ9.659-0.748
MRQ9.659TTM9.6590.000
TTM9.659YOY-42.577+52.236
TTM9.6595Y-50.208+59.867
5Y-50.20810Y8.795-59.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.911-2.437+11.348
MRQ9.659-2.599+12.258
TTM9.659-2.764+12.423
YOY-42.577-4.018-38.559
5Y-50.208-6.401-43.807
10Y8.795-6.590+15.385
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Biotest Aktiengesellschaft:

  • The EOD is -32.336. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -35.049. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -35.049. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-32.336MRQ-35.049+2.713
MRQ-35.049TTM-35.0490.000
TTM-35.049YOY-19.275-15.774
TTM-35.0495Y1.108-36.157
5Y1.10810Y-22.987+24.094
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-32.336-3.111-29.225
MRQ-35.049-3.321-31.728
TTM-35.049-3.598-31.451
YOY-19.275-5.480-13.795
5Y1.108-8.353+9.461
10Y-22.987-8.955-14.032
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Biotest is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.46 means the investor is paying €2.46 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Biotest Aktiengesellschaft:

  • The EOD is 2.268. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.459. Based on the equity, the company is underpriced. +1
  • The TTM is 2.459. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.268MRQ2.459-0.190
MRQ2.459TTM2.4590.000
TTM2.459YOY3.626-1.167
TTM2.4595Y2.864-0.405
5Y2.86410Y4.468-1.604
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.2682.051+0.217
MRQ2.4592.143+0.316
TTM2.4592.120+0.339
YOY3.6262.878+0.748
5Y2.8643.601-0.737
10Y4.4683.972+0.496
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Biotest Aktiengesellschaft compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--3.2303.2300%-0.235+107%0.019+17170%0.029+11103%
Book Value Per Share--12.60812.6080%9.378+34%10.962+15%10.778+17%
Current Ratio--1.9631.9630%4.757-59%4.289-54%4.031-51%
Debt To Asset Ratio--0.6550.6550%0.692-5%0.636+3%0.607+8%
Debt To Equity Ratio--1.8951.8950%2.242-15%1.785+6%1.592+19%
Dividend Per Share----0%0.020-100%0.016-100%0.060-100%
Eps--3.2093.2090%-0.799+125%-0.025+101%0.162+1878%
Free Cash Flow Per Share---0.884-0.8840%-1.764+99%-1.013+15%-1.451+64%
Free Cash Flow To Equity Per Share---1.056-1.0560%0.500-311%-0.064-94%-0.912-14%
Gross Profit Margin--0.6030.6030%2.551-76%3.823-84%3.740-84%
Intrinsic Value_10Y_max--9.371--------
Intrinsic Value_10Y_min---8.994--------
Intrinsic Value_1Y_max---0.387--------
Intrinsic Value_1Y_min---1.325--------
Intrinsic Value_3Y_max---0.153--------
Intrinsic Value_3Y_min---3.639--------
Intrinsic Value_5Y_max--1.301--------
Intrinsic Value_5Y_min---5.557--------
Market Cap565871020.000-117%1226715012.0001226715012.0000%1345429368.000-9%1204554998.880+2%2005045901.388-39%
Net Profit Margin--0.1860.1860%-0.061+133%-0.015+108%0.018+929%
Operating Margin--0.1900.1900%-0.025+113%0.004+4390%0.047+305%
Operating Ratio--0.8100.8100%1.016-20%0.990-18%0.994-19%
Pb Ratio2.268-8%2.4592.4590%3.626-32%2.864-14%4.468-45%
Pe Ratio8.911-8%9.6599.6590%-42.577+541%-50.208+620%8.795+10%
Price Per Share28.600-8%31.00031.0000%34.000-9%30.440+2%50.669-39%
Price To Free Cash Flow Ratio-32.336+8%-35.049-35.0490%-19.275-45%1.108-3264%-22.987-34%
Price To Total Gains Ratio8.856-8%9.5999.5990%-158.286+1749%-50.512+626%1802.626-99%
Quick Ratio--0.8450.8450%2.631-68%2.235-62%2.395-65%
Return On Assets--0.0880.0880%-0.026+130%-0.006+106%0.003+3170%
Return On Equity--0.2550.2550%-0.085+133%-0.016+106%-0.001+100%
Total Gains Per Share--3.2303.2300%-0.215+107%0.035+9161%0.089+3530%
Usd Book Value--537065850.000537065850.0000%399489150.000+34%466964170.000+15%459138015.000+17%
Usd Book Value Change Per Share--3.4773.4770%-0.253+107%0.020+17170%0.031+11103%
Usd Book Value Per Share--13.57213.5720%10.095+34%11.801+15%11.603+17%
Usd Dividend Per Share----0%0.022-100%0.017-100%0.065-100%
Usd Eps--3.4553.4550%-0.860+125%-0.027+101%0.175+1878%
Usd Free Cash Flow---37677498.924-37677498.9240%-75139700.000+99%-43167649.785+15%-61791099.892+64%
Usd Free Cash Flow Per Share---0.952-0.9520%-1.899+99%-1.091+15%-1.562+64%
Usd Free Cash Flow To Equity Per Share---1.137-1.1370%0.539-311%-0.069-94%-0.982-14%
Usd Market Cap609160153.030-117%1320558710.4181320558710.4180%1448354714.652-9%1296703456.294+2%2158431912.844-39%
Usd Price Per Share30.788-8%33.37233.3720%36.601-9%32.769+2%54.545-39%
Usd Profit--136715500.000136715500.0000%-34017400.000+125%-861200.000+101%7008015.000+1851%
Usd Revenue--736971900.000736971900.0000%555581650.000+33%563999880.000+31%551458655.000+34%
Usd Total Gains Per Share--3.4773.4770%-0.231+107%0.038+9161%0.096+3530%
 EOD+3 -5MRQTTM+0 -0YOY+25 -115Y+25 -1110Y+22 -14

3.2. Fundamental Score

Let's check the fundamental score of Biotest Aktiengesellschaft based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-158.911
Price to Book Ratio (EOD)Between0-12.268
Net Profit Margin (MRQ)Greater than00.186
Operating Margin (MRQ)Greater than00.190
Quick Ratio (MRQ)Greater than10.845
Current Ratio (MRQ)Greater than11.963
Debt to Asset Ratio (MRQ)Less than10.655
Debt to Equity Ratio (MRQ)Less than11.895
Return on Equity (MRQ)Greater than0.150.255
Return on Assets (MRQ)Greater than0.050.088
Total7/10 (70.0%)

3.3. Technical Score

Let's check the technical score of Biotest Aktiengesellschaft based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.982
Ma 20Greater thanMa 5028.870
Ma 50Greater thanMa 10027.920
Ma 100Greater thanMa 20028.994
OpenGreater thanClose28.500
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Accumulated Other Comprehensive Income  -3,9001,000-2,900900-2,0000-2,0003,1001,100
Income before Tax  -1,300-28,700-30,000-32,600-62,60031,800-30,800137,100106,300
Net Income  -4,700-26,700-31,400-31,900-63,30031,700-31,600158,600127,000
EBIT  -6,500-6,700-13,200-38,900-52,10039,100-13,000143,200130,200
Operating Income  -6,500-6,700-13,200-38,900-52,10039,100-13,000143,200130,200
Income Tax Expense  3,400-2,0001,400-700700100800-21,500-20,700
Net Income from Continuing Operations  -4,700-26,700-31,400-32,000-63,40031,700-31,700122,60090,900



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets1,444,300
Total Liabilities945,400
Total Stockholder Equity498,900
 As reported
Total Liabilities 945,400
Total Stockholder Equity+ 498,900
Total Assets = 1,444,300

Assets

Total Assets1,444,300
Total Current Assets756,500
Long-term Assets687,800
Total Current Assets
Cash And Cash Equivalents 118,500
Short-term Investments 200
Net Receivables 206,800
Inventory 419,100
Other Current Assets 11,900
Total Current Assets  (as reported)756,500
Total Current Assets  (calculated)756,500
+/-0
Long-term Assets
Property Plant Equipment 578,400
Goodwill 6,000
Intangible Assets 9,000
Long-term Assets Other 200
Long-term Assets  (as reported)687,800
Long-term Assets  (calculated)593,600
+/- 94,200

Liabilities & Shareholders' Equity

Total Current Liabilities385,300
Long-term Liabilities560,100
Total Stockholder Equity498,900
Total Current Liabilities
Short-term Debt 260,100
Short Long Term Debt 226,800
Accounts payable 78,100
Other Current Liabilities 46,900
Total Current Liabilities  (as reported)385,300
Total Current Liabilities  (calculated)611,900
+/- 226,600
Long-term Liabilities
Long term Debt 329,500
Capital Lease Obligations 57,800
Long-term Liabilities Other -300
Long-term Liabilities  (as reported)560,100
Long-term Liabilities  (calculated)387,000
+/- 173,100
Total Stockholder Equity
Common Stock39,600
Retained Earnings 238,400
Accumulated Other Comprehensive Income 1,100
Other Stockholders Equity 219,800
Total Stockholder Equity (as reported)498,900
Total Stockholder Equity (calculated)498,900
+/-0
Other
Capital Stock39,600
Cash and Short Term Investments 118,700
Common Stock Shares Outstanding 39,571
Current Deferred Revenue200
Liabilities and Stockholders Equity 1,444,300
Net Debt 571,300
Net Invested Capital 1,055,200
Net Working Capital 371,200
Property Plant and Equipment Gross 962,400
Short Long Term Debt Total 689,800



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-31
> Total Assets 
371,994
349,978
358,275
351,013
362,059
536,702
592,044
633,454
632,339
682,762
682,347
886,500
1,032,600
962,700
932,800
978,500
1,042,300
1,108,400
1,131,300
1,104,200
1,203,000
1,444,300
1,444,3001,203,0001,104,2001,131,3001,108,4001,042,300978,500932,800962,7001,032,600886,500682,347682,762632,339633,454592,044536,702362,059351,013358,275349,978371,994
   > Total Current Assets 
220,668
197,213
197,858
188,502
199,191
241,892
279,491
325,261
308,944
369,950
367,461
562,500
679,300
586,800
467,200
449,700
495,100
522,800
556,300
522,200
619,400
756,500
756,500619,400522,200556,300522,800495,100449,700467,200586,800679,300562,500367,461369,950308,944325,261279,491241,892199,191188,502197,858197,213220,668
       Cash And Cash Equivalents 
8,073
12,118
19,641
7,589
8,903
8,889
8,072
6,730
18,541
83,199
57,241
204,400
179,400
53,800
72,900
22,300
61,900
60,800
71,300
104,400
116,600
118,500
118,500116,600104,40071,30060,80061,90022,30072,90053,800179,400204,40057,24183,19918,5416,7308,0728,8898,9037,58919,64112,1188,073
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
54,700
99,900
10,000
5,900
44,200
24,900
17,900
13,100
20,000
200
20020,00013,10017,90024,90044,2005,90010,00099,90054,700000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
125,700
190,200
206,800
184,600
152,500
196,700
155,600
175,800
157,000
185,900
206,800
206,800185,900157,000175,800155,600196,700152,500184,600206,800190,200125,70000000000000
       Inventory 
129,896
117,223
116,664
108,362
104,755
116,871
156,554
170,326
148,711
152,983
184,216
227,000
246,000
218,700
170,800
146,900
208,300
280,100
290,100
244,600
293,800
419,100
419,100293,800244,600290,100280,100208,300146,900170,800218,700246,000227,000184,216152,983148,711170,326156,554116,871104,755108,362116,664117,223129,896
       Other Current Assets 
82,699
67,872
61,553
72,551
85,533
116,132
114,865
148,205
141,692
133,768
126,004
131,100
199,200
214,400
213,500
274,600
180,700
1,400
1,200
3,100
3,100
11,900
11,9003,1003,1001,2001,400180,700274,600213,500214,400199,200131,100126,004133,768141,692148,205114,865116,13285,53372,55161,55367,87282,699
   > Long-term Assets 
151,326
152,765
160,417
162,511
162,868
294,810
312,553
308,193
323,395
312,812
314,886
324,000
353,300
375,900
465,600
528,800
547,200
585,600
575,000
582,000
583,600
687,800
687,800583,600582,000575,000585,600547,200528,800465,600375,900353,300324,000314,886312,812323,395308,193312,553294,810162,868162,511160,417152,765151,326
       Property Plant Equipment 
147,031
149,443
154,221
108,741
108,181
143,405
209,786
231,955
230,749
234,857
244,576
254,900
282,300
317,200
414,900
477,100
512,700
547,900
548,200
550,000
547,800
578,400
578,400547,800550,000548,200547,900512,700477,100414,900317,200282,300254,900244,576234,857230,749231,955209,786143,405108,181108,741154,221149,443147,031
       Goodwill 
0
0
0
0
0
0
0
0
0
0
30,137
28,800
32,700
36,500
16,800
7,300
7,200
7,200
7,100
7,100
7,200
6,000
6,0007,2007,1007,1007,2007,2007,30016,80036,50032,70028,80030,1370000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
1,800
1,500
3,500
4,300
2,300
1,900
0
0
0
0
0
000001,9002,3004,3003,5001,5001,80000000000000
       Intangible Assets 
0
0
0
0
0
0
73,808
66,680
64,941
62,833
22,918
19,300
17,500
8,200
8,500
9,300
9,200
6,600
6,900
4,100
9,200
9,000
9,0009,2004,1006,9006,6009,2009,3008,5008,20017,50019,30022,91862,83364,94166,68073,808000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
39,000
54,600
109,300
243,900
216,500
227,200
251,600
249,700
90,400
0
0
0090,400249,700251,600227,200216,500243,900109,30054,60039,00000000000000
> Total Liabilities 
261,200
246,691
250,309
198,122
194,693
310,942
338,670
363,592
324,731
336,094
312,914
425,800
552,400
550,400
572,100
630,700
547,100
631,500
689,700
723,800
831,900
945,400
945,400831,900723,800689,700631,500547,100630,700572,100550,400552,400425,800312,914336,094324,731363,592338,670310,942194,693198,122250,309246,691261,200
   > Total Current Liabilities 
0
0
0
0
0
0
118,345
148,777
131,348
147,735
164,877
124,300
128,900
125,800
146,000
251,200
125,600
115,000
105,600
106,400
130,200
385,300
385,300130,200106,400105,600115,000125,600251,200146,000125,800128,900124,300164,877147,735131,348148,777118,345000000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
41,445
5,300
6,100
9,100
16,200
119,600
700
7,300
7,900
6,400
9,400
260,100
260,1009,4006,4007,9007,300700119,60016,2009,1006,1005,30041,4450000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
231,500
6,100
9,000
16,000
119,400
500
3,300
3,500
29,500
4,800
226,800
226,8004,80029,5003,5003,300500119,40016,0009,0006,100231,50000000000000
       Accounts payable 
22,053
14,819
16,588
0
0
0
48,730
40,583
42,779
34,678
47,373
51,400
55,500
53,100
62,800
65,000
73,400
52,200
42,000
38,800
51,100
78,100
78,10051,10038,80042,00052,20073,40065,00062,80053,10055,50051,40047,37334,67842,77940,58348,73000016,58814,81922,053
       Other Current Liabilities 
0
0
0
0
0
0
69,615
108,194
88,569
113,057
76,059
67,600
67,300
63,600
67,000
66,600
46,600
7,700
5,900
4,300
69,500
46,900
46,90069,5004,3005,9007,70046,60066,60067,00063,60067,30067,60076,059113,05788,569108,19469,615000000
   > Long-term Liabilities 
52,717
46,646
48,489
0
0
0
220,325
214,815
193,383
188,359
148,037
301,500
423,500
424,600
426,100
379,500
421,500
516,500
584,100
617,400
701,700
560,100
560,100701,700617,400584,100516,500421,500379,500426,100424,600423,500301,500148,037188,359193,383214,815220,32500048,48946,64652,717
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
75,300
97,700
89,100
96,100
92,700
92,800
113,600
121,600
121,000
0
0
00121,000121,600113,60092,80092,70096,10089,10097,70075,30000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
100
200
100
0
0
0
0
0
0
0
0000000100200100000000000000
> Total Stockholder Equity
106,210
100,421
104,084
166,537
176,637
222,493
248,925
264,761
301,564
346,572
369,324
460,600
480,100
412,200
360,500
347,600
495,000
476,900
441,600
380,400
371,100
498,900
498,900371,100380,400441,600476,900495,000347,600360,500412,200480,100460,600369,324346,572301,564264,761248,925222,493176,637166,537104,084100,421106,210
   Common Stock
20,480
20,480
20,480
0
27,296
30,025
30,025
30,025
30,025
30,025
30,025
33,800
33,800
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,60039,60039,60039,60039,60039,60039,60039,60039,60033,80033,80030,02530,02530,02530,02530,02530,02527,296020,48020,48020,480
   Retained Earnings Total Equity0000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
-157,410
-163,520
-184,904
-182,874
-203,200
-223,700
-309,100
-217,500
-226,400
-249,200
-3,900
-2,900
-2,000
-2,000
1,100
1,100-2,000-2,000-2,900-3,900-249,200-226,400-217,500-309,100-223,700-203,200-182,874-184,904-163,520-157,4100000000
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
85,730
79,941
83,604
0
133,300
176,946
193,158
209,063
234,592
270,194
305,891
208,700
208,700
200,000
219,800
200,000
200,000
219,800
219,800
219,800
219,800
219,800
219,800219,800219,800219,800219,800200,000200,000219,800200,000208,700208,700305,891270,194234,592209,063193,158176,946133,300083,60479,94185,730



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue684,600
Cost of Revenue-412,700
Gross Profit271,900271,900
 
Operating Income (+$)
Gross Profit271,900
Operating Expense-141,700
Operating Income130,200130,200
 
Operating Expense (+$)
Research Development66,200
Selling General Administrative30,600
Selling And Marketing Expenses50,400
Operating Expense141,700147,200
 
Net Interest Income (+$)
Interest Income3,600
Interest Expense-40,000
Other Finance Cost-3,900
Net Interest Income-40,300
 
Pretax Income (+$)
Operating Income130,200
Net Interest Income-40,300
Other Non-Operating Income Expenses0
Income Before Tax (EBT)106,300154,100
EBIT - interestExpense = 90,200
106,300
167,000
Interest Expense40,000
Earnings Before Interest and Taxes (EBIT)130,200146,300
Earnings Before Interest and Taxes (EBITDA)166,100
 
After tax Income (+$)
Income Before Tax106,300
Tax Provision-5,100
Net Income From Continuing Ops90,900101,200
Net Income127,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses554,400
Total Other Income/Expenses Net-23,90040,300
 

Technical Analysis of Biotest
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Biotest. The general trend of Biotest is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Biotest's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Biotest Aktiengesellschaft.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 29.90 < 30.20 < 30.40.

The bearish price targets are: 27.40 > 22.80.

Tweet this
Biotest Aktiengesellschaft Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Biotest Aktiengesellschaft. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Biotest Aktiengesellschaft Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Biotest Aktiengesellschaft. The current macd is 0.25099808.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Biotest price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Biotest. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Biotest price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Biotest Aktiengesellschaft Daily Moving Average Convergence/Divergence (MACD) ChartBiotest Aktiengesellschaft Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Biotest Aktiengesellschaft. The current adx is 19.04.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Biotest shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Biotest Aktiengesellschaft Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Biotest Aktiengesellschaft. The current sar is 29.81.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Biotest Aktiengesellschaft Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Biotest Aktiengesellschaft. The current rsi is 50.98. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Biotest Aktiengesellschaft Daily Relative Strength Index (RSI) ChartBiotest Aktiengesellschaft Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Biotest Aktiengesellschaft. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Biotest price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Biotest Aktiengesellschaft Daily Stochastic Oscillator ChartBiotest Aktiengesellschaft Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Biotest Aktiengesellschaft. The current cci is -106.32183908.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Biotest Aktiengesellschaft Daily Commodity Channel Index (CCI) ChartBiotest Aktiengesellschaft Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Biotest Aktiengesellschaft. The current cmo is -5.39112533.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Biotest Aktiengesellschaft Daily Chande Momentum Oscillator (CMO) ChartBiotest Aktiengesellschaft Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Biotest Aktiengesellschaft. The current willr is -88.88888889.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Biotest Aktiengesellschaft Daily Williams %R ChartBiotest Aktiengesellschaft Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Biotest Aktiengesellschaft.

Biotest Aktiengesellschaft Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Biotest Aktiengesellschaft. The current atr is 0.43001311.

Biotest Aktiengesellschaft Daily Average True Range (ATR) ChartBiotest Aktiengesellschaft Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Biotest Aktiengesellschaft. The current obv is 185,175.

Biotest Aktiengesellschaft Daily On-Balance Volume (OBV) ChartBiotest Aktiengesellschaft Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Biotest Aktiengesellschaft. The current mfi is 58.93.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Biotest Aktiengesellschaft Daily Money Flow Index (MFI) ChartBiotest Aktiengesellschaft Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Biotest Aktiengesellschaft.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-19ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-24MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-29MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Biotest Aktiengesellschaft Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Biotest Aktiengesellschaft based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.982
Ma 20Greater thanMa 5028.870
Ma 50Greater thanMa 10027.920
Ma 100Greater thanMa 20028.994
OpenGreater thanClose28.500
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Biotest with someone you think should read this too:
  • Are you bullish or bearish on Biotest? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Biotest? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Biotest Aktiengesellschaft

I send you an email if I find something interesting about Biotest Aktiengesellschaft.


Comments

How you think about this?

Leave a comment

Stay informed about Biotest Aktiengesellschaft.

Receive notifications about Biotest Aktiengesellschaft in your mailbox!